Leukemia Clinical Trial
Official title:
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia
Verified date | May 2023 |
Source | SWOG Cancer Research Network |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Pravastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Pravastatin may also help idarubicin and cytarabine work better by making cancer cells more sensitive to the drugs. Giving idarubicin and cytarabine together with pravastatin may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving idarubicin and cytarabine together with pravastatin works in treating patients with relapsed acute myeloid leukemia (AML). ADDITIONAL BACKGROUND: S0919 was initially designed for patients with relapsed acute myeloid leukemia (AML), where the patient's preceding remission had lasted ≥ 3 months. The null response rate was 30%. The study closed to accrual on Nov 1, 2012 after meeting the defined criterion for a positive study; and the results are being submitted to the American Society of Clinical Oncology meeting. Based on the promising results from this trial, the trial has now been amended to evaluate this therapeutic regimen in poor-risk patients (patients with newly diagnosed acute myeloid leukemia (AML) arising out of myelodysplastic syndrome (MDS), primary refractory acute myeloid leukemia (AML), and relapsed acute myeloid leukemia (AML) with the patient's preceding remission lasting < 6 months).
Status | Completed |
Enrollment | 115 |
Est. completion date | October 21, 2021 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Cohort 1 (Initial cohort: Relapsed AML with previous remission >/= 3 months) is permanently closed to accrual DISEASE CHARACTERISTICS - Patients must have a previous morphologically confirmed diagnosis of acute myeloid leukemia (AML). Note: This protocol uses the World Health Organization (WHO) diagnostic criteria for acute myeloid leukemia (AML) (see Section 4.1). Patients with acute promyelocytic leukemia (APL, FAB, M3) or blastic transformation of chronic myelogenous leukemia (CMML) are not eligible. - Patients must have received at least one prior chemotherapy regimen for their acute myeloid leukemia (AML) and they may have received any type of chemotherapy. They must have achieved complete remission (CR), lasting at least three months with their last induction regimen and they must have relapsed after the last regimen. Relapse must be documented by a bone marrow examination demonstrating > 5% blasts in the bone marrow not attributable to another cause. Refractory patients and patients who have received autologous or allogeneic stem cell transplantation are not eligible. Administration of hydroxyurea to control high white blood cell (WBC) count prior to, during and after registration is permitted. - Patients must not have symptomatic congestive heart failure, coronary artery disease, cardiomyopathy, or uncontrolled arrhythmias. Either an echocardiogram or multiple-gated acquisition (MUGA) scan with an ejection fraction = 45% must be obtained within 28 days prior to registration. (Either method for measuring cardiac function is acceptable, however, the same scan must be used throughout treatment and follow-up to monitor the patient for cardiac toxicity.) If patient has symptoms suggestive of ischemia or congestive heart failure after that cardiac evaluation was done, a repeat study must be obtained prior to registration. - Patients must have a serum creatinine < 2.0 mg/dl within 14 days prior to registration. - Patients must have a total bilirubin = 2.0 x Institutional Upper Limit of Normal (IULN) within 14 days prior to registration, unless the elevation is due primarily to elevated unconjugated hyperbilirubinemia secondary to Gilbert's syndrome or hemolysis and not to liver dysfunction. - Patients must have SGOT (AST) = 3.0 x IULN and SGPT (ALT) = 3.0 x IULN within 14 days prior to registration. Treatment may begin with SGOT/SGPT above those limits, if the abnormalities are thought to be due to the patient's leukemia. - Patients must have Zubrod performance status of 0-2 (see Section 10.8). - Patients must be = 18 years of age. - Patients must not have clinical evidence of leptomeningeal disease (a spinal tap does not need to be performed). - Patients not known to be HIV+ must be tested for HIV infection (the human immunodeficiency virus) within 14 days prior to registration (see Section 2.0 for justification). Patients who are HIV+ may be eligible providing they meet all of the following additional criteria within 14 days prior to registration: 1. Patient must have no history of AIDS defining events. 2. CD4 cells = 500/mm3. 3. Viral load of < 50 copies HIV mRNA/mm3 if on cART or < 25,000 copies HIV mRNA if not on cART. 4. No zidovudine or stavudine as part of cART. Patients who are HIV+ and do not meet all of these criteria will not be eligible for this study. - Patients with prior malignancy (other than AML) are eligible. However, the patient must be in remission from the prior malignancy and have completed all chemotherapy and radiotherapy at least 6 months prior to registration and all treatment related toxicities must have been resolved. NOTE: For patients with prior history of malignancy who have received anthracyclines or mediastinal/pericardial radiation in the past, the risk versus benefit of therapy should be weighed, particularly in the setting of receiving consolidation therapy. - Patients must not have a systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). - Southwest Oncology Group patients must be registered on SWOG-9007 ("Cytogenetic Studies in Leukemia Patients"). Collection of pretreatment marrow specimens must be completed within 28 days prior to registration. Pretreatment specimens of bone marrow (or peripheral blood if the marrow aspirate is a dry tap) must be submitted to an approved Southwest Oncology Group Cytogenetics Laboratory for cytogenetics analysis. Note that protocol SWOG-9007 also requires submission of specimens at additional timepoints. - Southwest Oncology Group patients must be offered participation in S9910 ("Leukemia Centralized Reference Laboratories and Tissue Repositories Ancillary"). If consent is given, collection of pretreatment blood and/or marrow specimens must be completed within 28 days prior to registration. If the patient consents to participate in S9910, pretreatment specimens of marrow and/or peripheral blood must be submitted to the Southwest Oncology Group Myeloid Repository at the University of New Mexico for cellular and molecular studies. Note that protocol S9910 also requests submission of specimens at additional timepoints. - Women of reproductive potential must have a negative pregnancy test within 14 days prior to registration. Patients must not be pregnant or nursing because of the teratogenic potential of the drugs used in this study. Women/men of reproductive potential must have agreed to use an effective contraceptive method. - All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. - At the time of patient registration, the treating institution's name and ID number must be provided to the Data Operations Center in Seattle in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the data base. Cohort 2 (MDS transformed to AML) is permanently closed to accrual AND Cohort 3 (relapsed/refractory AML) is permanently closed to accrual DISEASE CHARACTERISTICS: - For patients registered to relapsed/refractory (Cohort 3), morphologically confirmed diagnosis of acute myeloid leukemia (AML) - Patient registered to the myelodysplastic syndrome (MDS) transformed to acute myeloid leukemia (AML) cohort (Cohort 2) patients must have a previous morphologically confirmed diagnosis of myelodysplastic syndrome/chronic myelomonocytic leukemia (MDS/CMML). Patients may have received previous non-intensive therapy (such as: azacitidine, decitabine, low-dose cytarabine, lenalidomide) given treatment of myelodysplastic syndrome/chronic myelomonocytic leukemia (MDS/CMML) (with up to 20% blasts). At time of registration, patient must have morphologically confirmed diagnosis of acute myeloid leukemia (AML). - Patients with acute promyelocytic leukemia (i.e., APL, FAB M3) or blastic transformation of chronic myelogenous leukemia are not eligible - Patients must not have received autologous or allogeneic stem cell transplant. - Patients in the relapsed/refractory acute myeloid leukemia (AML) cohort (Cohort 3) must: - Have received = 1 prior chemotherapy regimen for acute myeloid leukemia (AML) - Any type of prior chemotherapy allowed - Administration of hydroxyurea to control high white blood cell (WBC) prior to, during, and after registration is permitted - Relapse must be documented by a bone marrow examination demonstrating > 5% blasts in the bone marrow not attributable to another cause - Patient must not have received chemo within 14 days prior to registration - Primary refractory patients eligible if, on Day 14 of previous chemo regimen, they have significant residual disease. Patients who received only hypomethylating agent or low dose therapy for Induction are not considered primary refractory for this study and are not eligible. - Relapsed patients must have achieved a complete remission (CR) or CR with incomplete blood count recovery that lasted < 6 months after the last induction regimen - No clinical evidence of leptomeningeal disease - Pretreatment (collected within 28 days of registration) cytogenetics must be performed on all patients. - Patients must have complete history and physical exam within 28 days prior to registration. PATIENT CHARACTERISTICS: - No symptomatic congestive heart failure, coronary artery disease, cardiomyopathy, or uncontrolled arrhythmias - Ejection fraction = 45% by echocardiogram or MUGA scan within 28 days prior to registration (or within 14 days prior to registration if the patient has received anthracycline in the 28 day window) - Zubrod performance status 0-2 - Serum creatinine = 2.0 times upper limit of normal (ULN) - Total bilirubin = 2.0 times ULN (unless elevation is primarily due to elevated unconjugated hyperbilirubinemia secondary to Gilbert's syndrome or hemolysis AND not due to liver dysfunction) - AST and ALT = 3.0 times ULN - Not pregnant or nursing and negative pregnancy test within 14 days prior to registration. Females of child-bearing potential must agree to use effective contraception - No HIV positivity unless the following criteria are met: - No history of AIDS-defining events - CD4 count = 500/mm³ - Viral load < 25,000 copies (< 50 copies if on combination antiretroviral therapy) - Not receiving zidovudine or stavudine as part of combination antiretroviral therapy - No uncontrolled systemic fungal, bacterial, viral, or other infection, defined as exhibiting ongoing signs/symptoms related to the infection with no improvement despite appropriate antibiotics or other treatment - Patients with prior malignancy (other than AML and MDS/CMML) eligible provided patient is in remission from that malignancy at least 6 months prior to registration. Except for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) treatment, all treatment related toxicities must have been resolved. |
Country | Name | City | State |
---|---|---|---|
United States | University of New Mexico Cancer Center | Albuquerque | New Mexico |
United States | Lehigh Valley Hospital-Cedar Crest | Allentown | Pennsylvania |
United States | Community Hospital of Anaconda | Anaconda | Montana |
United States | Cancer Care Center at Island Hospital | Anacortes | Washington |
United States | Michigan Cancer Research Consortium NCORP | Ann Arbor | Michigan |
United States | Saint Joseph Mercy Hospital | Ann Arbor | Michigan |
United States | Hospital District Sixth of Harper County | Anthony | Kansas |
United States | University of Colorado Cancer Center - Anschutz Cancer Pavilion | Aurora | Colorado |
United States | Saint Alphonsus Medical Center-Baker City | Baker City | Oregon |
United States | Hematology/Oncology Clinic LLP | Baton Rouge | Louisiana |
United States | PeaceHealth Saint Joseph Medical Center | Bellingham | Washington |
United States | Lehigh Valley Hospital - Muhlenberg | Bethlehem | Pennsylvania |
United States | Billings Clinic Cancer Center | Billings | Montana |
United States | Frontier Cancer Center and Blood Institute-Billings | Billings | Montana |
United States | Montana Cancer Consortium NCORP | Billings | Montana |
United States | Saint Vincent Healthcare | Billings | Montana |
United States | University of Alabama at Birmingham Cancer Center | Birmingham | Alabama |
United States | Illinois CancerCare-Bloomington | Bloomington | Illinois |
United States | Saint Joseph Medical Center | Bloomington | Illinois |
United States | Saint Alphonsus Cancer Care Center-Boise | Boise | Idaho |
United States | Parkland Health Center-Bonne Terre | Bonne Terre | Missouri |
United States | Bozeman Deaconess Hospital | Bozeman | Montana |
United States | Harrison HealthPartners Hematology and Oncology-Bremerton | Bremerton | Washington |
United States | IHA Hematology Oncology Consultants-Brighton | Brighton | Michigan |
United States | Saint Joseph Mercy Brighton | Brighton | Michigan |
United States | Highline Medical Center-Main Campus | Burien | Washington |
United States | Saint James Community Hospital and Cancer Treatment Center | Butte | Montana |
United States | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell | Idaho |
United States | IHA Hematology Oncology Consultants-Canton | Canton | Michigan |
United States | Illinois CancerCare-Canton | Canton | Illinois |
United States | Saint Joseph Mercy Canton Health Center | Canton | Michigan |
United States | Saint Francis Medical Center | Cape Girardeau | Missouri |
United States | Southeast Cancer Center | Cape Girardeau | Missouri |
United States | Memorial Hospital of Carbondale | Carbondale | Illinois |
United States | Caro Cancer Center | Caro | Michigan |
United States | SIH Cancer Institute | Carterville | Illinois |
United States | Illinois CancerCare-Carthage | Carthage | Illinois |
United States | Rocky Mountain Oncology | Casper | Wyoming |
United States | Centralia Oncology Clinic | Centralia | Illinois |
United States | Cancer Center of Kansas - Chanute | Chanute | Kansas |
United States | IHA Hematology Oncology Consultants-Chelsea | Chelsea | Michigan |
United States | Saint Joseph Mercy Chelsea | Chelsea | Michigan |
United States | Hematology Oncology Consultants-Clarkston | Clarkston | Michigan |
United States | Newland Medical Associates-Clarkston | Clarkston | Michigan |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Southeastern Medical Oncology Center-Clinton | Clinton | North Carolina |
United States | Big Horn Basin Cancer Center | Cody | Wyoming |
United States | Billings Clinic-Cody | Cody | Wyoming |
United States | Kootenai Medical Center | Coeur d'Alene | Idaho |
United States | Beaumont Hospital-Dearborn | Dearborn | Michigan |
United States | Cancer Care Center of Decatur | Decatur | Illinois |
United States | Decatur Memorial Hospital | Decatur | Illinois |
United States | Saint John Hospital and Medical Center | Detroit | Michigan |
United States | Cancer Center of Kansas - Dodge City | Dodge City | Kansas |
United States | Great Lakes Cancer Management Specialists-Doctors Park | East China Township | Michigan |
United States | Swedish Medical Center-Edmonds | Edmonds | Washington |
United States | Crossroads Cancer Center | Effingham | Illinois |
United States | Cancer Center of Kansas - El Dorado | El Dorado | Kansas |
United States | Walter Knox Memorial Hospital | Emmett | Idaho |
United States | Illinois CancerCare-Eureka | Eureka | Illinois |
United States | Genesee Cancer and Blood Disease Treatment Center | Flint | Michigan |
United States | Genesee Hematology Oncology PC | Flint | Michigan |
United States | Genesys Hurley Cancer Institute | Flint | Michigan |
United States | Hurley Medical Center | Flint | Michigan |
United States | Cancer Center of Kansas - Fort Scott | Fort Scott | Kansas |
United States | Illinois CancerCare-Galesburg | Galesburg | Illinois |
United States | Western Illinois Cancer Treatment Center | Galesburg | Illinois |
United States | Southeastern Medical Oncology Center-Goldsboro | Goldsboro | North Carolina |
United States | Wayne Memorial Hospital | Goldsboro | North Carolina |
United States | Benefis Healthcare- Sletten Cancer Institute | Great Falls | Montana |
United States | Great Falls Clinic | Great Falls | Montana |
United States | Great Lakes Cancer Management Specialists-Van Elslander Cancer Center | Grosse Pointe Woods | Michigan |
United States | Lymphoma Clinic of Michigan | Grosse Pointe Woods | Michigan |
United States | Michigan Breast Specialists-Grosse Pointe Woods | Grosse Pointe Woods | Michigan |
United States | Smilow Cancer Hospital Care Center at Saint Francis | Hartford | Connecticut |
United States | Saint Peter's Community Hospital | Helena | Montana |
United States | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston | Texas |
United States | Baylor Saint Luke's Medical Center | Houston | Texas |
United States | Ben Taub General Hospital | Houston | Texas |
United States | Michael E DeBakey VA Medical Center | Houston | Texas |
United States | Cancer Center of Kansas-Independence | Independence | Kansas |
United States | Swedish Cancer Institute-Issaquah | Issaquah | Washington |
United States | Allegiance Health | Jackson | Michigan |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Southeastern Medical Oncology Center-Jacksonville | Jacksonville | North Carolina |
United States | Capital Region Medical Center-Goldschmidt Cancer Center | Jefferson City | Missouri |
United States | Glacier Oncology PLLC | Kalispell | Montana |
United States | Kalispell Regional Medical Center | Kalispell | Montana |
United States | Kadlec Clinic Hematology and Oncology | Kennewick | Washington |
United States | Illinois CancerCare-Kewanee Clinic | Kewanee | Illinois |
United States | Cancer Center of Kansas-Kingman | Kingman | Kansas |
United States | Seattle Cancer Care Alliance at EvergreenHealth | Kirkland | Washington |
United States | Sparrow Hospital | Lansing | Michigan |
United States | Lawrence Memorial Hospital | Lawrence | Kansas |
United States | Cancer Center of Kansas-Liberal | Liberal | Kansas |
United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
United States | Hope Cancer Clinic | Livonia | Michigan |
United States | Saint Mary Mercy Hospital | Livonia | Michigan |
United States | Hematology Oncology Associates East PC | Macomb | Michigan |
United States | Illinois CancerCare-Macomb | Macomb | Illinois |
United States | Michigan Breast Specialists-Macomb Township | Macomb | Michigan |
United States | Cancer Center of Kansas-Manhattan | Manhattan | Kansas |
United States | Loyola University Medical Center | Maywood | Illinois |
United States | Cancer Center of Kansas - McPherson | McPherson | Kansas |
United States | Idaho Urologic Institute-Meridian | Meridian | Idaho |
United States | Froedtert and the Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Community Medical Hospital | Missoula | Montana |
United States | Montana Cancer Specialists | Missoula | Montana |
United States | Saint Patrick Hospital - Community Hospital | Missoula | Montana |
United States | Skagit Valley Hospital | Mount Vernon | Washington |
United States | Saint Alphonsus Medical Center-Nampa | Nampa | Idaho |
United States | Tulane University Health Sciences Center | New Orleans | Louisiana |
United States | Cancer Center of Kansas - Newton | Newton | Kansas |
United States | Saint Alphonsus Medical Center-Ontario | Ontario | Oregon |
United States | Illinois CancerCare-Ottawa Clinic | Ottawa | Illinois |
United States | Radiation Oncology of Northern Illinois | Ottawa | Illinois |
United States | Stanford Cancer Institute | Palo Alto | California |
United States | Cancer Center of Kansas - Parsons | Parsons | Kansas |
United States | Illinois CancerCare-Pekin | Pekin | Illinois |
United States | OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center | Pekin | Illinois |
United States | Illinois CancerCare-Peoria | Peoria | Illinois |
United States | Methodist Medical Center of Illinois | Peoria | Illinois |
United States | OSF Saint Francis Medical Center | Peoria | Illinois |
United States | OSF Saint Francis Radiation Oncology at Peoria Cancer Center | Peoria | Illinois |
United States | Illinois CancerCare-Peru | Peru | Illinois |
United States | Valley Radiation Oncology | Peru | Illinois |
United States | 21st Century Oncology-Pontiac | Pontiac | Michigan |
United States | Hope Cancer Center | Pontiac | Michigan |
United States | Newland Medical Associates-Pontiac | Pontiac | Michigan |
United States | Saint Joseph Mercy Oakland | Pontiac | Michigan |
United States | Lake Huron Medical Center | Port Huron | Michigan |
United States | Oregon Health and Science University | Portland | Oregon |
United States | Kootenai Cancer Center | Post Falls | Idaho |
United States | Harrison HealthPartners Hematology and Oncology-Poulsbo | Poulsbo | Washington |
United States | Cancer Center of Kansas - Pratt | Pratt | Kansas |
United States | Illinois CancerCare-Princeton | Princeton | Illinois |
United States | University of Rochester | Rochester | New York |
United States | Great Lakes Cancer Management Specialists-Rochester Hills | Rochester Hills | Michigan |
United States | Oncology Hematology Associates of Saginaw Valley PC | Saginaw | Michigan |
United States | Saint Mary's of Michigan | Saginaw | Michigan |
United States | Missouri Baptist Medical Center | Saint Louis | Missouri |
United States | Sainte Genevieve County Memorial Hospital | Sainte Genevieve | Missouri |
United States | Cancer Center of Kansas - Salina | Salina | Kansas |
United States | Kootenai Cancer Clinic | Sandpoint | Idaho |
United States | Fred Hutchinson Cancer Research Center | Seattle | Washington |
United States | Group Health Cooperative-Seattle | Seattle | Washington |
United States | Harborview Medical Center | Seattle | Washington |
United States | Minor and James Medical PLLC | Seattle | Washington |
United States | Swedish Medical Center-Ballard Campus | Seattle | Washington |
United States | Swedish Medical Center-First Hill | Seattle | Washington |
United States | University of Washington Medical Center | Seattle | Washington |
United States | United General Hospital | Sedro-Woolley | Washington |
United States | Welch Cancer Center | Sheridan | Wyoming |
United States | Louisiana State University Health Sciences Center Shreveport | Shreveport | Louisiana |
United States | Cancer Care Northwest - Spokane South | Spokane | Washington |
United States | Evergreen Hematology and Oncology PS | Spokane | Washington |
United States | Rockwood Clinic | Spokane | Washington |
United States | Central Illinois Hematology Oncology Center | Springfield | Illinois |
United States | Memorial Medical Center | Springfield | Illinois |
United States | Southern Illinois University School of Medicine | Springfield | Illinois |
United States | Springfield Clinic | Springfield | Illinois |
United States | Bhadresh Nayak MD PC-Sterling Heights | Sterling Heights | Michigan |
United States | Missouri Baptist Sullivan Hospital | Sullivan | Missouri |
United States | Missouri Baptist Outpatient Center-Sunset Hills | Sunset Hills | Missouri |
United States | Cancer Care Specialists of Illinois-Swansea | Swansea | Illinois |
United States | Memorial and Saint Elizabeth's Health Care Services LLP | Swansea | Illinois |
United States | Moffitt Cancer Center | Tampa | Florida |
United States | Great Lakes Cancer Management Specialists-Macomb Professional Building | Warren | Michigan |
United States | Macomb Hematology Oncology PC | Warren | Michigan |
United States | Michigan Breast Specialists-Warren | Warren | Michigan |
United States | Saint John Macomb-Oakland Hospital | Warren | Michigan |
United States | Cancer Center of Kansas - Wellington | Wellington | Kansas |
United States | Wenatchee Valley Hospital and Clinics | Wenatchee | Washington |
United States | Saint Mary's Oncology/Hematology Associates of West Branch | West Branch | Michigan |
United States | Associates In Womens Health | Wichita | Kansas |
United States | Cancer Center of Kansas - Wichita | Wichita | Kansas |
United States | Cancer Center of Kansas-Wichita Medical Arts Tower | Wichita | Kansas |
United States | Via Christi Regional Medical Center | Wichita | Kansas |
United States | Wesley Medical Center | Wichita | Kansas |
United States | Wichita NCI Community Oncology Research Program | Wichita | Kansas |
United States | Southeastern Medical Oncology Center-Wilson | Wilson | North Carolina |
United States | Cancer Center of Kansas - Winfield | Winfield | Kansas |
United States | Southeast Clinical Oncology Research (SCOR) Consortium NCORP | Winston-Salem | North Carolina |
United States | Huron Gastroenterology PC | Ypsilanti | Michigan |
United States | IHA Hematology Oncology Consultants-Ann Arbor | Ypsilanti | Michigan |
Lead Sponsor | Collaborator |
---|---|
SWOG Cancer Research Network | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Correlation Between Pre-study Cytogenetic Features and Response | 5 years | ||
Other | Overall Survival (OS) | OS is calculated for all participants from the date of initial registration on study until death from any cause. Observations for participants last known to be alive were censored. | OS assessed for up to 5 years, median OS reported | |
Other | Relapse-free Survival (RFS) | RFS is calculated for participants who have achieved a complete response (CR) or CR with incomplete blood count recovery (CRi). RFS will be measured from the date of CR or CRi until relapse from CR or CRi for death from any cause. Observation is censored at the date of last follow-up for patients last known to be alive without report of relapse. Per the Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, morphologic complete remission requires that the patient achieve the morphologic leukemia-free state and have an absolute neutrophil count of more than 1,000/µL and platelets of = 100,000/µL. |
RFS assessed for up to 5 years, median RFS reported | |
Primary | Complete Remission (CR) Rate (Including CR With Incomplete Recovery) | Participants who achieved morphological complete remission with or without incomplete blood count recovery. Per the Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, morphologic complete remission requires that the patient achieve the morphologic leukemia-free state and have an absolute neutrophil count of more than 1,000/µL and platelets of = 100,000/µL. |
Up to 5 years after registration | |
Secondary | Frequency and Severity of Toxicity as Assessed by NCI CTCAE Version 3.0 | Number of patients with Grade 3-5 adverse events that were possibly, probably or definitely related to study drug are reported by given type of adverse event | Up to 5 years post registration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |